A next-generation whole parasite bovine Babesia vaccine.

下一代全寄生虫牛巴贝虫疫苗。

• 批准号: DP230102313
• 负责人: Dr Danielle Stanisic
• 金额: $ 42.84万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2023
• 资助国家: 澳大利亚
• 起止时间: 2023-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP230102313
• 关键词: next; generation; whole; parasite; bovine

In Australia, Babesia parasites cause most of the severe and often fatal cases of cattle-tick fever, a globally significant tick-borne disease. It can be prevented by a live-attenuated parasite vaccine which has critical limitations of a 4-day shelf-life and risk of severe disease if administered to adult cattle. This project aims to evaluate in cattle a novel whole parasite Babesia bovis vaccine that cannot cause disease and can be preserved as an off-the-shelf product without losing efficacy. The expected outcome is a significantly improved vaccine for a major infectious disease that affects primary food production. As the disease imposes a major economic burden, it will have great benefit for the Australian livestock industry.

在澳大利亚，由巴贝斯虫寄生虫引起的牛蜱热病是一种全球性的重要疾病，大多数严重病例往往是致命的。它可以通过减毒活寄生虫疫苗来预防，这种疫苗的关键限制是4天的保质期，如果给成年牛接种，就有严重疾病的风险。该项目旨在评估一种新型的牛巴贝斯虫全寄生虫疫苗，该疫苗不会引起疾病，可以作为现成产品保存而不会失去效力。预期的结果是对一种影响初级粮食生产的主要传染病的疫苗有显著的改进。由于这种疾病造成了重大的经济负担，它将给澳大利亚畜牧业带来巨大的好处。